Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
4(80%)
Results Posted
400%(4 trials)

Phase Distribution

Ph phase_2
1
20%
Ph not_applicable
3
60%
Ph phase_4
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 4Post-market surveillance
1(20.0%)
N/ANon-phased studies
3(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Completed(1)

Detailed Status

Active, not recruiting3
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (20.0%)
Phase 41 (20.0%)
N/A3 (60.0%)

Trials by Status

completed120%
recruiting120%
active_not_recruiting360%

Recent Activity

4 active trials
Showing 5 of 5
recruitingphase_4

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

NCT05376878
active_not_recruitingnot_applicable

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

NCT02226276
active_not_recruitingphase_2

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

NCT02827877
active_not_recruitingnot_applicable

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

NCT01093612
completednot_applicable

64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer

NCT01939275

Clinical Trials (5)

Showing 5 of 5 trials
NCT05376878Phase 4

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Recruiting
NCT02226276Not Applicable

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Active Not Recruiting
NCT02827877Phase 2

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Active Not Recruiting
NCT01093612Not Applicable

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Active Not Recruiting
NCT01939275Not Applicable

64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer

Completed

All 5 trials loaded

Drug Details

Intervention Type
RADIATION
Total Trials
5